Artur Shvetcov

This study identifies a consistent proteomic signature of APOE ε4 across plasma and CSF, revealing cell-type-specific molecular effects in brain tissues associated with Alzheimer's disease risk.

The paper creates an integrated atlas linking RNA and protein expression across human tissues and cell types, identifying genes that reliably translate RNA into protein.

The paper benchmarks proteomic biomarkers and drug targets in patient-derived cerebral organoids against clinical cohorts, finding they detect most candidates and replicate disease changes in a quarter of reproducible markers.

This paper evaluates the adequacy of using 3-5 iPSC donor lines to control for genetic heterogeneity and finds that these sample sizes are insufficient for reliable detection or estimation of donor-level variance.

This study identifies an APOE ε4-associated systemic immune proteomic signature in ALS that predicts disease progression independently of clinical features.

The paper presents a harmonized framework for analyzing large-scale plasma proteomics data across neurodegenerative diseases, identifying disease-specific circulating signatures and biomarkers.

This study identifies an APOE4-specific cerebrospinal fluid proteome signature using machine learning, independent of Alzheimer's disease diagnosis and associated with increased risk of cognitive impairment.

This review evaluates estrogen and estrogenic compounds' neuroprotective effects in spinal cord injury, finding they reduce inflammation and improve functional outcomes.

This study uses AI-driven meta-analysis of brain gene expression data to identify novel gene candidates and highlights mitochondrial dysfunction in Alzheimer's disease.

This study shows tamoxifen protects against early cognitive and cellular damage caused by hippocampal silent infarcts in rats within 24 hours.